why on earth has this exciting pharma company been ignored her for the last 3.5 years? ...... lots has happened in that time, generally for the better on the longer view ..... from a purely chart point of view, the 200 mda is rising quite steadily, with sp recovering well after a sharp fall, and now, after a brief tease below, is therefore probably worth buying on that basis alone.

From memory, Shares mag was also quite excited about this stock a week or two back, even though that medium has supported some classic stinkers in its time

It was a bit of a shock initially, I agree, but sp picking up now. Analyst meeting and webcast at 14:00 - will be interesting to hear what questions are raised.

is this worth buying now?

in my opinion, yes ...... SHP is a very well established and proven pharma company with real products

i've just bought - sp will pick up well - expect good profit on this one now

in fact easy money!

hard to justify the grumpy reaction by sp ..... prob mainly short term profit taking, though i suppose the CEO is not jumping up and won with excitement at the prospects - but all the better for it imo


Shire Pharmaceuticals Plc. posted first-quarter sales of $702 million, up 33 percent, and slightly ahead of expectations, with the company reaffirming its financial guidance for this year and predicting positive growth through to 2010.

Analysts' consensus in a Thomson poll was for sales of 700 million in the quarter.

Diluted EPS was 22.7 cents, compared with 21.3 cents in the previous year.

The company also said its Vyvanse ADHD product would generate sales at 'the lower end' of the $350 million to $400 million range.

Vyvanse achieved a 6.9 percent share of the U.S. ADHD market in the quarter, with sales of $54.4 million, the company said.

CEO Matthew Emmens said: 'It's been a good start to the year with sales growth from new and established products achieving our expectations.'

Emmens affirmed the company's previous financial guidance for the year and predicted positive revenue growth through to 2010.

is this worth buying now as its much lower since i last asked.....glad i didny buy at the time

SHP certain to be whacked open along with other pharmas due to "proposals will include average price cuts of about 5 percent for existing medicines, however this will be sweetened by assurances of more rapid and widespread uptake by the National Health Service of higher-priced new treatments".

not yet on view, but clearly from the reaction SHP's numbers were at lesat very satisfactory ...... this could really fly as the heavy short selling (surely, judging by recent sp movement) is forced to close

all looks pretty promising to me .......


Shire Ltd. upped its guidance for 2008 revenue growth be at least 20 percent above year ago-levels, as it delivered a 35 percent rise in second-quarter sales.

The biopharma company had earlier forecast full-year revenue growth in the mid to high teens.

CEO Angus Russell told a newswire conference the upgraded guidance reflected strong product sales in the first half and the momentum that this will carry into the second half. He cautioned that second-half comparisons would be more difficult because the products had done well in the same period in 2007.

Total sales for the June quarter came in at $776 million, with product sales rising 40 percent to $706 million. New product sales contributed $243 million, or 34 percent, of the total. The company reiterated its guidance that Vyvanse sales for the year would be at the lower end of a $350 million to $400 million scale.

Shire will also book costs of around $150 million to cover the discontinuation of its Dynepo kidney disease product. The company said the emergence of biosimilar generics have 'proved challenging' for Dynepo.

Overall spending on research and development will increase to $500 million, compared with guidance of $465 million to $490 million. This reflects the acquisition of its Metzym product and an increased research tempo for core products.

i rather like the look of the chart (see below), with sp now nudging above 200 dma and NY very strong indeed tonight.

having sold my IEC, i now have some reasonable funds in hand, and shall almost certainly have a dabble here in the morning .... i like the company anyway, and i would have thought that sooner or later it will be gobbled up anyway

very much against the trend, sp has been recovering sharply ..... certainly they had good figures, but i don't recollect any strong buy notes coming out and nor is there a new rns, so is this just a quality pharma being bought as a defensive stock or is there a predator in the wings?

volume no heavier than usual, but sp now +33 at 898 ...... no obvious reason, but chart is encouraging IF sp can break and hold above 200 dma

typical reaction to first class figures = selling on the news ..... i shall top up ....
please see edited (for those seemingly incapable of such, please learn!) comment from the chairman


"2008 saw excellent growth across the business. 2009 will see continued
momentum in our business as we drive growth in existing products, pursue
launches of new products and continue to develop our strong pipeline of drugs.
We reiterate the earnings guidance framework for 2009 published in our third
quarter earnings statement, and our aspiration of growing sales in the mid
teens range on average between 2009 and 2015. We look forward confidently to
the future."

"i shall top up" aka as I'd best average down!! Cynic the expert strikes again. Give us that list for some short ideas, cheers.

certainly seem to have called SHP wrong for the moment, but it's a seriously sound and solid company so shall prob stay with it ..... short suggestions? .... WOS, WPP and maybe ASC

SHp seriously sound and solid??? Nice waste of a big wad of cash on Renovo I do recall.

call it what you like .... you are fully entitled to your own opinion .... surprised you haven't shorted

kate ... you're turn to admit you're wrong!! - lol

today's announcement of collaboration with GSK is not only interesting in its own right, but just may be the start of the long slow dance towards ultimate merger ..... henc +40p at opening

Express says, "Shire said to be possible bid target" ...... might be true one day!